Document is current
Any future updates will be listed below
-
Authors
Strzelczyk, Adam https://orcid.org/0000-0001-6288-9915
Klotz, Kerstin Alexandra https://orcid.org/0000-0002-1601-5384
Mayer, Thomas
von Podewils, Felix https://orcid.org/0000-0002-3134-8697
Knake, Susanne https://orcid.org/0000-0002-6298-0513
Kurlemann, Gerhard
Herold, Luise
Immisch, Ilka
Buhleier, Elisa
Rosenow, Felix https://orcid.org/0000-0002-3989-7471
Schubert-Bast, Susanne https://orcid.org/0000-0003-1545-7364
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 10 June 2025
First Online: 12 July 2025
Declarations
:
: Adam Strzelczyk received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Longboard, Neuraxpharm, Stoke Therapeutics, Takeda, UCB Pharma, and UNEEG medical. Kerstin Alexandra Klotz received speaker’s honoraria from Biocodex, Eisai, Jazz Pharmaceuticals, and UCB Pharma. Thomas Mayer received speaker’s honoraria from Jazz Pharmaceuticals, UCB, and Angelin Pharma. Felix von Podewils received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, UCB Pharma, Nutricia Milupa GmbH, Neuraxpharm, and Bial. Susanne Knake received speaker’s honoraria from Bial, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Merck Serono, and UCB. Gerhard Kurlemann received speaker’s honoraria from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB Pharma, Neuraxpharm, Stada Arzneimittel, Precisis GmbH, and Alexion Pharmaceuticals. Luise Herold and Elisa Buhleier have no conflicts of interest to disclose. Ilka Immisch received personal fees from Angelini Pharma, Jazz Pharmaceuticals, and Precisis. Felix Rosenow received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Dr. Schär Deutschland GmbH, Eisai GMBH, Jazz Pharmaceuticals, Nutricia Milupa GmbH, Takeda, UCB Pharma, and Vitaflo Deutschland GmbH. Susanne Schubert-Bast received personal fees and grants from Angelini Pharma, Biocodex, Biomarin, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, and UCB Pharma.
: The analysis was approved by the ethics committee of the University of Frankfurt. Informed consent was waived because of the retrospective nature of the chart reviews.
